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alongside an inhibitor directed against the inactivating
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that resist modification by some inactivating enzymes,
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group transfer presented by aminoglycoside modifyingDepartment of Biochemistry
McMaster University enzymes virtually guarantees that a new aminoglycoside
will not be effective against all resistance mechanisms.1200 Main Street West
Hamilton, Ontario L8N 3Z5 Broad-spectrum inhibitors directed against more than
one class of modifying enzyme would therefore be highlyCanada
2 Department of Microbiology and Immunology desirable and would allow the rescue of aminoglycoside
antibiotic activity, analogous to the employment ofUniversity of British Columbia
6174 University Boulevard -lactamase inhibitors to overcome penicillin resis-
tance [3].Vancouver, British Columbia V6T 1Z3
Canada The three-dimensional structures of representative
members of all three classes of aminoglycoside modi-
fying enzymes have directed our efforts to identify inhibi-
tors active against resistance enzymes. For example,Summary
the aminoglycoside phosphotransferase APH(3)-IIIa
was shown to be structurally homologous to eukaryoticThe action of aminoglycoside antibiotics is inhibited
protein kinases [4], prompting a screen of protein kinaseby chemical modification catalyzed by aminoglycoside
inhibitors from which many compounds were deter-inactivating enzymes, which bind these cationic sac-
mined to inhibit APHs [5]. The AACs and ANTs also havecharides with active site pockets that contain a pre-
eukaryotic homologs, and in particular, AAC(3)-Ia [6] andponderance of negatively charged residues. In this
AAC(6)-Ii [7] belong to the large GCN5-related N-ace-study, it was observed that several cationic antimicro-
tyltransferase superfamily, which includes the eukary-bial peptides, representing different structural classes,
otic histone acetyltransferases GCN5 and Hat1. Thesecould serve as inhibitors of such aminoglycoside resis-
structural studies have correlated well with functionaltance enzymes. The bovine antimicrobial peptide in-
studies that have shown that APHs [8] and AACs [7] candolicidin and synthetic analogs appeared to be espe-
phosphorylate and acetylate peptides, respectively. Incially effective against a range of resistance enzymes,
general, positively charged peptides are favored, likelyinhibiting enzymes belonging to both aminoglycoside
owing to the prevalence of negatively charged residuesphosphotransferase and aminoglycoside acetyltrans-
in the active site pockets of aminoglycoside modifyingferase classes, where the mode of action was depen-
enzymes (Figure 1). The anionic depression present indent on the class of antibiotic resistance enzyme.
the resistance enzymes is thought to attract positivelyThese peptides represent the first example of broad-
charged antibiotics and act as an electronic scaffoldspectrum inhibitors of aminoglycoside resistance en-
for the efficient binding of a variety of aminoglycosidezymes.
structures. Given this common binding site feature, pos-
itively charged molecules could be developed that inter-
Introduction fere with this interaction with aminoglycosides and lead
to broad-spectrum inhibition of resistance activity.
Clinical resistance to the aminocyclitol-aminoglycoside Given that aminoglycoside resistance enzymes share
antibiotics is most often associated with the presence this common binding strategy and that many of them
of inactivating enzymes. These enzymes, classified as also bind peptides and proteins, we hypothesized that
aminoglycoside acetyltransferases (AACs), aminoglyco- cationic peptides could serve as lead molecules in the
side nucleotidyltransferases (ANTs), or aminoglyco- development of a universal aminoglycoside resistance
side phosphotransferases (APHs), catalyze the transfer inhibitor. Cationic peptides are also good starting points
of acetyl, adenosine monophosphate, or phosphate for these studies, as many of them have antimicrobial
groups, respectively, onto the aminoglycoside antibiot- activity themselves [9]. While the site of action for some
ics [1]. These modifications block the antibiotic’s inter- of these peptides appears to be the bacterial cyto-
action with its target, the 30S ribosomal subunit [2], plasmic membrane, there is evidence for penetration of
leading to a resistance phenotype. Aminoglycoside re- others into the cytoplasm where aminoglycoside resis-
sistance is now widespread among clinically important tance enzymes are active [10, 11].
bacteria and is impacting the utility of these bactericidal In this study, we have screened a variety of cationic
agents. Overcoming aminoglycoside resistance re- antimicrobial peptides against three well-characterized
quires the development of new antibiotics that are aminoglycoside resistance enzymes, APH(3)-IIIa,
impervious to modification by the enzymes, or in an AAC(6)-Ii, and AAC(6)-APH(2″). APH(3)-IIIa (KanR) and
alternative approach, the use of an aminoglycoside AAC(6)-APH(2″) (GentR) are two of the most common
and important resistance determinants in gram-positive
bacterial pathogens [12], whereas AAC(6)-Ii is a chro-*Correspondence: wrightge@mcmaster.ca
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Figure 1. The Common Anionic Depression
Found in the Active Sites of Aminoglycoside
Resistance Enzymes
(A) Electrostatic surface potential map of the
aminoglycoside acetyltransferase AAC(6)-Ii
(PDB 1B87). Red and blue indicate the re-
gions of the enzyme with the greatest electro-
negative and electropositive characters, re-
spectively.
(B) Electrostatic surface potential map of the
aminoglycoside phosphotransferase APH(3)-
IIIa (PDB 1J71), with colors denoted as in (A).
mosomally encoded determinant found in the difficult- Ii, whereas gramicidin S, a bacterium-derived cyclic
decapeptide, was the best inhibitor of AAC(6)-Ie.to-treat Enterococcus faecium that lends low-level intrin-
sic resistance to many aminoglycosides and obviates For the most part, the two aminoglycoside phospho-
transferases surveyed, APH(3)-IIIa and APH(2″)-Ia (theaminoglycoside/penicillin synergy in these organisms
[13]. We have identified cationic peptide inhibitors of kinase activity of the bifunctional AAC(6)-APH(2″) en-
zyme), had similar peptide inhibitor profiles (Table 1).both aminoglycoside phosphotransferases and amino-
glycoside acetyltransferases that show similar affinity The -hairpin-structured peptide protegrin (PG1) ap-
peared to be the best inhibitor of the aminoglycosidefor binding to the enzymes as natural substrates. More-
over, the bovine antimicrobial peptide indolicidin and phosphotransferases, and indolicidin and its analog,
CP10A, had efficient inhibitory activity against both en-its analogs were shown to inhibit enzymes belonging to
both the aminoglycoside phosphotransferase and amino- zymes. CP11CN weakly inhibited APH(3)-IIIa but did
not show any activity against APH(2″)-Ia, suggesting aglycoside acetyltransferase classes of resistance en-
zymes. These compounds represent the first broad-spec- limited selectivity between the aminoglycoside phos-
photransferases.trum inhibitors of aminoglycoside modifying enzymes.
The best peptide inhibitors were not necessarily those
with the greatest positive charge, demonstrating that
Results and Discussion inhibitory peptides make specific amino acid contacts
with the enzymes and their interaction is not exclusively
Antimicrobial Peptides Inhibit Aminoglycoside dictated by ionic interactions. Indolicidin and its analog,
Resistance Enzymes CP10A, were especially effective in inhibiting the resis-
Several structural classes of cationic peptides were tance enzymes with IC50s in the low to mid-micromolar
screened against three aminoglycoside modifying en- range for three of the four enzyme activities (Table 1).
zymes representing two classes of aminoglycoside re- The more highly charged indolicidin analog CP11CN
sistance enzymes, the APHs and the AACs, which are was only effective against AAC(6)-Ii and APH(3)-IIIa,
most prevalent in gram-positive pathogens (Table 1). although it was a significantly weaker inhibitor of
Most of these peptides, except protegrin 1 and gramici- APH(3)-IIIa compared to CP10A and indolicidin.
din S, are predicted to be unstructured in free solution
and only adopt the structures described in Table 1 upon
interaction with membranes [14]. An Aminoglycoside Acetyltransferase Can Modify
Antimicrobial PeptidesThe two aminoglycoside acetyltransferases, AAC(6)-
Ii and AAC(6)-Ie (the acetyltransferase activity associ- AAC(6)-Ii has shown the ability to acetylate peptides [7],
which correlates with its structural similarity to histoneated with the bifunctional enzyme AAC(6)-APH(2″)),
showed different peptide affinities (Table 1). Neither in- acetyltransferases. It was therefore important to deter-
mine if the aminoglycoside acetyltransferases coulddolicidin nor its analogs, CP11CN or CP10A, appeared
to inhibit AAC(6)-Ie, whereas these peptides were good modify the peptides analyzed in our screen. This would
be especially critical for understanding the mechanisminhibitors of AAC(6)-Ii. On the other hand, the -helical-
forming peptides CP29 and CP2600 effectively inhibited of action for those peptides determined to be inhibitors
in the initial screen.AAC(6)-Ie, but did not have an effect against AAC(6)-
Ii. CP10A appeared to be the best inhibitor of AAC(6)- Several Lys-rich cationic peptides were found to be
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Table 1. Cationic Antimicrobial Peptides that Inhibit the Aminoglycoside Antibiotic Resistance Enzymes AAC(6)-Ii, AAC(6)-APH(2),
and APH(3)-IIIa
IC50 (M)c
Charge at
Peptidea Sequenceb pH 7 Structure References AAC(6)-Iic AAC(6)-Ie APH(2″)-Ia APH(3)-IIIa
CP29 KWKSFIKKLTTAVKKVLTTGLPALIS 6 -helical [21] n.a.d 21  9 n.a. n.a.
CP2600 KWKSFIKKLTSAAKKVTTAAKPLTK 7 -helical unpublished n.a. 38  9 n.a. n.a.
CM3 KWKKFIKSLTKAAKTVVKTAKKPLIV 9 -helical [21] 24  1 n.a. n.a. n.a.
Indolicidin ILPWKWPWWPWRR-NH2 4 Extended [22] 13  1 n.a. 64  5 11  2
CP11CN ILKKWPWWPWRRK-NH2 6 Extended [22] 23  4 n.a. n.a. 51 10
CP10A ILAWKWAWWAWRR-NH2 4 -helical [22] 4.4  0.2 n.a. 36  6 11  1
PG1 RGGRLCYCRRRFCVCVGR 6 -hairpin [23] n.a. n.a. 20  4 5.2  0.3
Gramicidin S (cyclic) LFdPVOLFdPVO 2 -sheet [22] n.a. 14  2 n.a. n.a.
a In addition to these peptides, the following -helical peptides were screened against one or more aminoglycoside modifying enzymes (CP26,
CEME, CEMA, CP1, and CP2) but did not show any significant inhibitory activity [22].
b For gramicidin S, the superscript d indicates D enantiomer, and O is the one letter code for ornithine. All other amino acid residues are
described by their one letter code.
c For the aminoglycoside acetyltransferases, the IC50s for AAC(6)-Ii and AAC(6)-Ie were determined in the presence of 50 M acetyl CoA and
50 M kanamycin A, and 100 M acetyl CoA and 40 M kanamycin A, respectively, using the aminoglycoside acetyltransferase assay described
in Experimental Procedures. For the aminoglycoside phosphotransferases, the IC50s were determined in the presence of 1000 M ATP and
100 M kanamycin A, using the kinase assay described in Experimental Procedures.
d No inhibitory activity for this peptide against this enzyme target.
acetylated by AAC(6)-Ii (Table 2). The peptides dis- Indolicidin Analogs Inhibit Aminoglycoside
Phosphotransferases and Aminoglycosideplayed KM values similar to those of aminoglycosides,
Acetyltransferases through Differentbut with much lower turnover rates, comparable to those
Modes of Actionof previously known peptide substrates, such as poly-L-
As indolicidin and its analog CP10A were able to inhibitlysine [7]. The observation that AAC(6)-Ii could catalyze
both APHs and AAC(6)-Ii, we compared the mode ofacetylation of the antimicrobial peptides CM3 and
action between the two classes to gain insight into theCP11CN had no effect on their antibacterial properties
structural requirements for efficient inhibition by thesewhen tested against bacteria expressing the AAC(6)-Ii
compounds. Toward the first goal, we determined theresistance enzyme (data not shown). Thus, despite the
inhibition patterns with respect to AAC(6)-Ii and the twofact that these peptides can be modified by AAC(6)-Ii,
APH enzymes.the presence of this aminoglycoside resistance enzyme
With AAC(6)-Ii, CP10A demonstrated a competitivedoes not confer resistance to these cationic peptides,
inhibition pattern with respect to the aminoglycosideauguring well for a “resistance-free” environment for the
substrate kanamycin A (Figure 2A) and a noncompetitivedevelopment of cationic antimicrobial peptides.
pattern with respect to acetyl CoA (Figure 2B). This clas-
The peptides were also tested as substrates for
sical pattern of inhibition suggests that CP10A binds at
AAC(6)-Ie, but no acetylation activity was detected or near the aminoglycoside binding pocket and does
(data not shown). This is consistent with our previous not make any interactions with the acetyl CoA binding
unpublished studies with AAC(6)-Ie, where we have pocket (Table 3).
been unable to identify a peptide substrate for this en- In contrast, a more complex situation arises in inhibi-
zyme activity. AAC(6)-Ie and AAC(6)-Ii do not share a tion patterns determined with the aminoglycoside phos-
high sequence homology [15], and AAC(6)-Ie may be photransferases, APH(3)-IIIa and APH(2″)-Ia, where the
structurally different from AAC(6)-Ii in important ways, peptide inhibitors demonstrated noncompetitive pat-
such that it is unable to accept peptide substrates. How- terns with respect to both aminoglycoside (Figure 2C)
ever, as evidenced by the inhibition data, both enzymes and ATP (Figure 2D, Table 3). These results suggest that
bound peptides and their aminoglycoside modifying ac- the peptide inhibitors have multiple binding modes to
the APH class of resistance enzyme. The inhibition pat-tivities were reduced by that interaction.
Table 2. Acetylation of Cationic Peptides by AAC(6)-Ii
Substrate KM (M) kcat (sec1) kcat/KM (M1sec1)
Kanamycin Aa 19.9  8.8 0.816  0.207 4.60  104
Poly-L Lysineb 17.1  1.4 0.004  0.001 2.23  102
CM3 27  12 0.03  0.01 1.1  103
CP11CN 25  14 0.04  0.01 1.7  103
MS178c 16  7 0.01  0.00 2.7  102
a [19]
b [7]
c Peptide MS178 has the sequence of GIGKFLKKAKKFGKATVKILKK (NH2) in single amino acid letter code.
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Figure 2. The Inhibition Patterns of Aminoglycoside Acetyltransferases and Phosphotransferases by the Peptide CP10A
(A) Inhibition of AAC(6)-Ii with kanamycin B as the variable substrate and acetyl CoA as the saturating substrate. The concentrations of CP10A
are as follows: 0 (open circle), 5 (closed circle), 10 (open square), and 20 (closed square) M.
(B) Inhibition of AAC(6)-Ii with acetyl CoA as the variable substrate and kanamycin B as the saturating substrate. The concentrations of
CP10A are as follows: 0 (open circle), 10 (closed circle), 20 (open square), and 40 (closed square) M.
(C) Inhibition of APH(2″)-Ia with kanamycin A as the variable substrate and ATP as the saturating substrate. The concentrations of CP10A are
as follows: 0 (open circle), 5 (closed circle), and 10 (open square) M.
(D) Inhibition of APH(2″)-Ia with ATP as the variable substrate and kanamycin A as the saturating substrate. The concentrations of CP10A are
as follows: 0 (open circle), 5 (closed circle), 10 (open square), and 40 (open triangle) M.
terns demonstrate that the peptides bind both to free dues of CP10A (GW15) did not inhibit either APH(3)-IIIa
or AAC(6)-Ii; however, a peptide composed of the fiveenzyme and to enzyme-substrate complexes, and also
C-terminal residues (GW11) was able to weakly inhibitsuggests that the peptides do not bind simply to either
APH(3)-IIIa (Table 4). This suggests that the most impor-the aminoglycoside binding site or the ATP binding
tant binding interaction to APH(3)-IIIa occurs with thepocket, but influence both sites directly or indirectly.
C-terminal proportion of CP10A. However, inhibition
was significantly increased as additional residues were
Structure-Activity Relationships of Indolicidin added onto the N terminus, where the addition of hy-
Analog CP10A drophobic residues had the largest impact on changes
The indolicidin analog CP10A demonstrated similar af- in IC50 (Table 4). This result suggests that hydrophobic
finity as aminoglycoside substrates, with Kis in the mid interactions and van der Waals forces also play impor-
to low micromolar range, to both AAC and APH classes tant roles in the interactions between peptide and resis-
of antibiotic resistance enzymes (Table 3). Our initial tance enzyme.
hypothesis was that these peptides would inhibit the With either APH(3)-IIIa or AAC(6)-Ii, maximum inhibi-
aminoglycoside resistance enzymes by binding primar- tion occurred only with full-length CP10A (Table 4).
ily through electrostatic interactions. Consistent with CP10A is predicted to adopt an amphipathic helix struc-
this hypothesis, increasing the salt concentration had a ture with one face primarily hydrophobic and the other
negative impact on IC50 for CP10A with both AAC(6)-Ii positively charged (Figure 3C). To determine the poten-
(Figure 3A) and APH(3)-IIIa (Figure 3B). tial importance of this secondary structure and the
To gain further insight into the important interactions placement of positively charged amino acid residues in
between the peptide and the enzymes, we assayed the the peptide, we tested the resistance enzymes against
resistance enzymes against a number of fragments of peptides GW27, which exchanges residues 5 and 7 in
CP10A, and GW28, which exchanges residues 11 andCP10A. A peptide consisting of the six N-terminal resi-
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Table 3. Ki Determinations for Indolicidin and Its Analogs with the Aminoglycoside Resistance Enzymes
Enzyme Inhibitor Variable Substrate Patterna Kis (M) Kii (M)
APH(2″)-Ia indolicidin kanamycin A NC 22.1  1.7 b
ATP NC 23.8  3.4 b
CP10A kanamycin A NC 10.1  0.8 b
ATP NC 7.66  0.61 b
APH(3)-IIIa indolicidin kanamycin A NC 14.6  2.1 b
ATP NC 10.3  1.4 b
CP10A kanamycin A NC 30.5  4.6 b
ATP NC 13.8  1.1 b
CP11CN kanamycin A NC 51.2  5.2 b
ATP NC 73.0  28.2 b
AAC(6)-Ii indolicidin ribostamycin C 4.23  0.96
acetyl CoA NC 38.0  1.7 b
CP10A kanamycin B C 2.41  0.60
acetyl CoA mixed 4.76  1.33 31.7  8.3
a The patterns were either competitive (C), true noncompetitive (NC), or mixed inhibition and characterized according to Experimental Proce-
dures.
b In true noncompetitive inhibition, Kis 	 Kii.
Figure 3. The Nature of the Interactions between the Peptide CP10A and the Aminoglycoside Resistance Enzymes AAC(6)-Ii and APH(3)-
IIIa
(A) Effect of salt on the inhibitory activity of CP10A on AAC(6)-Ii. IC50 were determined in the presence of 50 M acetyl CoA and 50 M
kanamycin A.
(B) Effect of salt on the inhibitory activity of CP10A on APH(3)-IIIa. IC50 were determined in the presence of 100 M ATP and 60 M kanamycin A.
(C) Helical wheel diagram for CP10A. CP10A has the ability to form an amphipathic helix with positive charged amino acid residues on one
face and primarily hydrophobic amino acid residues on the other face. The propensity for -helical formation increases in the presence of
negatively charged lipids. This secondary structure may be important for the peptide’s interactions with the negatively charged surface patches
of aminoglycoside resistance enzymes.
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Table 4. Structure-Activity Relationship for the Peptide CP10A with APH(3)-IIIa and AAC(6)-Ii
IC50 (M)a
Peptide Sequence APH(3)-IIIa AAC(6)-Ii
CP10A ILAWKWAWWAWRR 8.5  0.7 4.4  0.2
GW22 LAWKWAWWAWRR 22  1 10  2
GW21 AWKWAWWAWRR 16  1 13  1
GW20 WKWAWWAWRR 31  3 17  3
GW19 KWAWWAWRR 79  7 No inhibition
GW18 WAWWAWRR 55  6 No inhibition
GW17 AWWAWRR 
100 No inhibition
GW16 WWAWRR 
100 No inhibition
GW11 WAWRR 400 No inhibition
GW15 ILAWKA No inhibition No inhibition
GW27 ILAWAWKWWAWRR 9.0  1.4 10  1
GW28 ILAWKWAWWARWR 5.0  0.5 5.8  1.0
a Determined in the presence of 100 M ATP and 60 M kanamycin A for APH(3)-IIIa, and 50 M acetyl CoA and 50 M kanamycin A for
AAC(6)-Ii.
12 in CP10A. These peptides have the same amino acid side binding pocket in AAC(6)-Ii, where the enzyme
can acetylate selected peptides. This result suggestscomposition and charge as CP10A, but with disrupted
amphipathic properties. GW28 was a slightly better in- that if there are important intracellular targets for cat-
ionic antimicrobial peptides, their efficacy could behibitor of APH(3)-IIIa than was CP10A; however, CP10A
was still the best inhibitor of AAC(6)-Ii where GW27 was potentially diminished by promiscuous aminoglyco-
side acetyltransferases. For aminoglycoside phospho-2.3-fold less potent in inhibiting the enzyme than CP10A
(Table 4). Considering these relatively minor effects on transferases, the peptides appear to interact with both
cofactor and aminoglycoside binding pockets, sug-inhibition, the positioning of the positively charged
amino acid residues has little impact on inhibitory activ- gesting that they may bind in a variety of conforma-
tions, where both electrostatic and hydrophobic inter-ity against the resistance enzymes. This is not com-
pletely unexpected, as there are a number of negatively actions play critical roles. These experiments set the
stage for further structure-based development of thecharged residues in the resistance enzymes that could
interact with the positively charged amino acid residues peptides to provide insight into the requirements of
potent small molecule inhibitors capable of overcom-in the peptides, depending on the nature of the peptide.
This is encouraging as it suggests that there is enough ing antibiotic resistance associated with a number of
aminoglycoside modifying enzymes.flexibility in the peptide-resistance enzyme interaction
such that the peptides have the ability to attenuate a
Experimental Proceduresbroad range of resistance activity by adopting the most
energetically favorable conformations dependent upon
Chemicals
the available interactions in the different enzymes. -NADH, phosphoenol pyruvate, and pyruvate kinase/lactate dehy-
While there is evidence to suggest that some cationic drogenase enzymes were from Sigma (St. Louis, MO). Kanamycin
A and gentamicin were from Bioshop (Burlington, ON, Canada). 4,4-peptides do enter the cell [10, 11], none of the peptides
dithiodipyridine and acetyl CoA were from Amersham Pharmaciawe examined in this study showed synergistic antimicro-
(Baie d’Urfe, PQ, Canada). Antimicrobial peptides were synthesizedbial properties with aminoglycosides in organisms har-
at the University of British Columbia’s Nucleic Acid and Proteinboring resistance genes (not shown).
Sequencing Facility using N-(9-fluorenyl)methoxy carbonyl (Fmoc)
chemistry and were purified by reversed phase high-pressure liquid
chromatography. The peptide purity was confirmed by mass spec-Significance
trometry.
APH(3)-IIIa [16], AAC(6)-APH(2″) [17, 18], and AAC(6)-Ii [19] were
Aminoglycoside phosphotransferase and acetyltrans- purified as previously described.
ferases inactivate their antibiotic substrates, render-
ing these important molecules clinically obsolete. One APH and AAC Kinetic Assays
The phosphotransferase assay employed has previously been de-major complication of the treatment of aminoglyco-
scribed [16]. The assay measures the production of ADP, generatedside antibiotic resistance is the large variety of inacti-
upon aminoglycoside phosphorylation, and couples that productionvating enzymes. However, aminoglycoside resistance
to the oxidation of -NADH using the enzymes pyruvate kinase and
enzymes share a common anionic depression in their lactate dehydrogenase. The rate of ADP production was determined
active sites, and this common structural motif can be by monitoring the decrease in absorbance at 340 nm.
Kanamycin acetylation by AAC(6)-Ii and AAC(6)-Ie was moni-exploited in inhibitor design. We have demonstrated
tored by the in situ titration of free coenzyme A product with 4,4-that positively charged peptides inhibit an array of
dithiodipyridine as previously described [17, 19]. Kinetic parametersaminoglycoside resistance enzymes. Moreover, indol-
for those cationic peptides behaving as AAC(6)-Ii substrates wereicidin and its analogs potently inhibit both phospho-
determined using [1-14C] acetyl-CoA and a phosphocellulose bind-
transferases and acetyltransferases, although the ing assay described previously [7]. Reaction mixtures typically con-
mode of inhibition is different between the classes of tained 25 mM HEPES (pH 7.5), 2 mM EDTA, 0.10 Ci [1-14C]Ac-CoA,
and 40 pmoles pure AAC(6)-Ii with varying concentrations of poly-enzyme. The peptides likely bind to the aminoglyco-
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L-lysine (as positive control) or cationic peptide and were allowed Received: December 9, 2002
Revised: February 3, 2003to proceed for 45 min.
Initial rates were fit to the Michaelis-Menton equation (1) using Accepted: February 3, 2003
Grafit 4.0 [20]:
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